Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixed results in phase 2. The new ...
Discover Alabama's 2026 football commits and stay informed about recruitment updates and player commitments for the upcoming season.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback